Purpose To review the available evidence on the ocular safety and efficacy of anti-vascular
endothelial growth factor (VEGF) agents for the treatment of retinopathy of prematurity (ROP) …

Abstract Background Retinopathy of Prematurity (ROP) is one of the most common causes of
childhood blindness worldwide. Comparisons of anti-VEGF and laser treatments in ROP are …

Importance Anti–vascular endothelial growth factor (VEGF) therapies are a novel treatment
option in retinopathy of prematurity (ROP). Data on dosing, efficacy, and safety are …

Purpose The primary endpoint results from the comparing alternative ranibizumab dosages
for safety and efficacy in retinopathy of prematurity (CARE‐ROP) core study identified …

Aim Retinopathy of prematurity (ROP) is a major morbidity in preterm infants causing visual
impairment including blindness. Prevention and timely treatment are critical. We investigated …

Background Retinopathy of prematurity (ROP) is a severe complication of preterm birth and
can lead to severe visual impairment or even blindness if untreated. The incidence of ROP …

AIM To compare the efficacy and safety between laser therapy and anti-vascular endothelial
growth factor (VEGF) agents intravitreal injection monotherapy in type-1 retinopathy of …

Retinopathy of prematurity (ROP) represents a vasoproliferative disease, especially in
newborns and infants, which can potentially affect and damage the vision. Despite recent …

Treatment complications are substantially different for the two modalities in common use
today. In more severe cases, risk of poor structural outcome and myopia favour treatment …

Purpose To report practice patterns of intravitreal injections of anti-VEGF for retinopathy of
prematurity (ROP) and outcomes data with a focus on retreatments and complications …